X-ray structure of dopamine transporter elucidates antidepressant mechanism

Nature

Volumn 503, Issue 7474, 2013, Pages 85-90

  Penmatsa, Aravind ^a   Wang, Kevin H ^a   Gouaux, Eric ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DOPAMINE TRANSPORTER; LEUCINE; NEUROTRANSMITTER; NORTRIPTYLINE; TRYPTOPHAN;

CRYSTAL STRUCTURE; DRUG; MEMBRANE; SUBSTRATE; X-RAY;

ANIMAL CELL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; CYTOPLASM; DROSOPHILA MELANOGASTER; MOLECULAR INTERACTION; NEUROTRANSMITTER UPTAKE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; SYNAPSE; THERMOSTABILITY; X RAY;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BACTERIAL PROTEINS; BINDING SITES; CHOLESTEROL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DROSOPHILA MELANOGASTER; IONS; MODELS, MOLECULAR; NORTRIPTYLINE; PROTEIN CONFORMATION; PROTEIN STABILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE;

DROSOPHILA MELANOGASTER; EUKARYOTA; PROKARYOTA;

EID: 84887404259     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12533     Document Type: Article

References (61)

1. Jessell, T. M. & Kandel, E. R. Synaptic transmission: a bidirectional and selfmodifiable form of cell-cell communication. Cell 72, (Suppl), 1-30 (1993).
2. Masson, J., Sagne, C., Hamon, M. & El Mestikawy, S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51, 439-464 (1999).
3. Kristensen, A. S. et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol. Rev. 63, 585-640 (2011).
4. Rudnick, G. Ion-coupled neurotransmitter transport: thermodynamic vs. kinetic determinations of stoichiometry. Methods Enzymol. 296, 233-247 (1998).
5. Radian, R., Bendahan, A. & Kanner, B. I. Purification and identification of the functional sodium-and chloride-coupled c-aminobutyric acid transport glycoprotein from rat brain. J. Biol. Chem. 261, 15437-15441 (1986).
6. Waldman, I. D. et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet. 63, 1767-1776 (1998).
7. Shannon, J. R. et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N. Engl. J. Med. 342, 541-549 (2000).
8. Meldrum, B. S. Neurotransmission in epilepsy. Epilepsia 36 (suppl. 1), 30-35 (1995).
9. Kurian, M. A. et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J. Clin. Invest. 119, 1595-1603 (2009).
10. Kuhn, R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am. J. Psychiatry 115, 459-464 (1958).
11. Axelrod, J.,Whitby, L. G.&Hertting, G. Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science 133, 383-384 (1961).
12. Berton, O. & Nestler, E. J. New approaches to antidepressant drug discovery: beyond monoamines. Nature Rev. Neurosci. 7, 137-151 (2006).
13. Pletscher, A. The discovery of antidepressants: a winding path. Experientia 47, 4-8 (1991).
14. Anderson, I. M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 58, 19-36 (2000).
15. Yamashita, A., Singh, S. K., Kawate, T., Jin, Y. & Gouaux, E. Crystal structure of a bacterial homologue ofNa1/Cl-dependent neurotransmitter transporters.Nature 437, 215-223 (2005).
16. Singh, S. K., Piscitelli, C. L., Yamashita, A.& Gouaux, E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science 322, 1655-1661 (2008).
17. Krishnamurthy, H.&Gouaux, E. X-ray structures of LeuTin substrate-free outwardopen and apo inward-open states. Nature 481, 469-474 (2012).
18. Beuming, T. et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap.Nature Neurosci. 11, 780-789 (2008).
19. Sørensen, L. et al. Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket. J. Biol. Chem. 287, 43694-43707 (2012).
20. Pörzgen, P., Park, S. K., Hirsh, J., Sonders, M. S. & Amara, S. G. The antidepressantsensitive dopamine transporter in Drosophilamelanogaster: a primordial carrier for catecholamines. Mol. Pharmacol. 59, 83-95 (2001).
21. Serrano-Vega, M. J., Magnani, F., Shibata, Y. & Tate, C. G. Conformational thermostabilization of the b1-adrenergic receptor in a detergent-resistant form. Proc. Natl Acad. Sci. USA 105, 877-882 (2008).
22. Tatsumi, M., Groshan, K., Blakely, R. D. & Richelson, E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340, 249-258 (1997).
23. Torres, G. E. et al. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J. Biol. Chem. 278, 2731-2739 (2003).
24. Sitte, H. H., Farhan, H. & Javitch, J. A. Sodium-dependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking. Mol. Interv. 4, 38-47 (2004).
25. Li, L. B. et al. The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J. Biol. Chem. 279, 21012-21020 (2004).
26. Chen, R. et al. Direct evidence that two cysteines in the dopamine transporter form a disulfide bond. Mol. Cell. Biochem. 298, 41-48 (2007).
27. Norregaard, L., Frederiksen, D., Nielsen, E. O. & Gether, U. Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO J. 17, 4266-4273 (1998).
28. Buck, K. J. & Amara, S. G. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol. Pharmacol. 48, 1030-1037 (1995).
29. Chen, J. G., Sachpatzidis, A.& Rudnick, G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J. Biol. Chem. 272, 28321-28327 (1997).
30. Henry, L. K. et al. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem. 281, 2012-2023 (2006).
31. Bismuth, Y., Kavanaugh, M. P.& Kanner, B. I. Tyrosine 140 of the c-aminobutyric acid transporter GAT-1 plays a critical role in neurotransmitter recognition. J. Biol. Chem. 272, 16096-16102 (1997).
32. Kitayama,S. et al.Dopaminetransporter site-directedmutations differentially alter substrate transport and cocaine binding. Proc. Natl Acad. Sci. USA 89, 7782-7785 (1992).
33. Andersen, J. et al. Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. J. Biol. Chem. 284, 10276-10284 (2009).
34. Talvenheimo, J., Fishkes, H., Nelson, P.J. & Rudnick, G. The serotonin transporterimipramine "receptor". J. Biol. Chem. 258, 6115-6119 (1983).
35. Singh, S. K., Yamashita, A. & Gouaux, E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448, 952-956 (2007).
36. Zhou, Z. et al. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317, 1390-1393 (2007).
37. Zhou, Z. et al. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nature Struct. Mol. Biol. 16, 652-657 (2009).
38. Harding, M. M.Metal-ligand geometry relevant to proteins andin proteins: sodium and potassium. Acta Crystallogr. D 58, 872-874 (2002).
39. Forrest, L. R., Tavoulari, S., Zhang, Y. W., Rudnick, G. & Honig, B. Identification of a chloride ion binding site in Na1/Cl2-dependent transporters. Proc. Natl Acad. Sci. USA 104, 12761-12766 (2007).
40. Zomot, E. et al. Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature 449, 726-730 (2007).
41. Kantcheva, A. K. et al. Chloride binding site of neurotransmitter sodium symporters. Proc. Natl Acad. Sci. USA 110, 8489-8494 (2013).
42. Tavoulari, S., Forrest, L. R. & Rudnick, G. Fluoxetine (Prozac) binding to serotonin transporter ismodulated by chloride and conformational changes. J. Neurosci. 29, 9635-9643 (2009).
43. Scanlon, S. M., Williams, D. C. & Schloss, P.Membrane cholesterol modulates serotonin transporter activity. Biochemistry 40, 10507-10513 (2001).
44. North, P.& Fleischer, S. Alteration of synaptic membrane cholesterol/phospholipid ratio using a lipid transfer protein. Effect on c-aminobutyric acid uptake. J. Biol. Chem. 258, 1242-1253 (1983).
45. Hong, W. C. & Amara, S. G. Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J. Biol. Chem. 285, 32616-32626 (2010).
46. Bennett, E. R., Su, H.& Kanner, B. I. Mutation of arginine 44 of GAT-1, a (Na11Cl2-coupled c-aminobutyric acid transporter from rat brain, impairs net flux but not exchange. J. Biol. Chem. 275, 34106-34113 (2000).
47. Cao, Y., Li, M., Mager, S. & Lester, H. A. Amino acid residues that control pH modulationof transport-associated current inmammalian serotonintransporters. J. Neurosci. 18, 7739-7749 (1998).
48. Loland, C. J., Norregaard, L., Litman, T. & Gether, U. Generation of an activating Zn21 switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc. Natl Acad. Sci. USA 99, 1683-1688 (2002).
49. Holton, K. L., Loder, M. K. & Melikian, H. E. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nature Neurosci. 8, 881-888 (2005).
50. Kawate, T. & Gouaux, E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 14, 673-681 (2006).
51. Dukkipati, A., Park, H. H.,Waghray, D., Fischer, S.&Garcia, K. C. BacMamsystemfor high-level expression of recombinant soluble and membrane glycoproteins for structural studies. Protein Expr. Purif. 62, 160-170 (2008).
52. Reeves, P.J., Callewaert, N.,Contreras, R.&Khorana, H. G. Structure and functionin rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N- acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl Acad. Sci. USA 99, 13419-13424 (2002).
53. Baconguis, I. & Gouaux, E. Structural plasticity and dynamic selectivity of acidsensing ion channel-spider toxin complexes. Nature 489, 400-405 (2012).
54. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
55. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
56. Emsley, P.& Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).
57. Afonine, P.V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D 68, 352-367 (2012).
58. Terwilliger, T. C. et al. Iterativemodel building, structure refinement and density modificationwith thePHENIXAutoBuildwizard. ActaCrystallogr.D64,61- 69(2008).
59. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
60. Quick, M. & Javitch, J. A. Monitoring the function of membrane transport proteins in detergent-solubilized form. Proc. Natl Acad. Sci. USA 104, 3603-3608 (2007).
61. Giros, B. et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42, 383-390 (1992).